JAZZ - Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes
Jazz Pharmaceuticals (NASDAQ: JAZZ) and GW Pharmaceuticals are now under the same corporate roof. The two companies announced Wednesday that Jazz's acquisition of GW has been completed. This brings the $7.6 billion cash-and-stock deal , first announced in early February, to a close.
In the companies' joint press release, Jazz CEO Bruce Cozadd was quoted as saying that the closing "mark[s] a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint."
Image source: Getty Images.
For further details see:
Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes